Alamar Biosciences reported a 68% revenue increase to $33.5 million in Q3 2026, driven by strong demand for its precision proteomics platform. The company raised its full-year 2026 revenue guidance to $121-$123 million, up 64% from 2025, reflecting growth in instrument sales, consumables, and services. Strategic collaborations with UK Biobank and GSK aim to advance early disease detection and precision medicine. Despite higher operating expenses and a net loss of $13.3 million, Alamar remains well-funded with $231.5 million in cash and investments, positioning it for continued growth.
Alamar Biosciences reported strong Q3 2026 results and raised its full-year revenue guidance. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: out of 150 priced US health stocks, 92 rose and 55 fell. Notable movers include INO at USD 1.65 with a 12.96% drop, IOVA at USD 8.86 with a 10.47% gain, and DNA at USD 10.74 with a 9.04% gain.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
